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Abstract.  Heparin-binding EGF-like growth factor 
(HB-EGF), but not EGF, binds to cell surface heparan 
sulfate proteoglycan (HSPG). This was demonstrated 
in (a) the binding of mI-HB-EGF to mutant CHO 
cells deficient in HS production was diminished by 
70%  compared to wild-type CHO cells, (b) the bind- 
ing of 125I-HB-EGF to CHO cells and bovine aortic 
smooth muscle cells (BASMC) was diminished 80% 
by heparitinase or chlorate treatment, and (c) ~zsI- 
EGF did not bind to CHO cells and its binding to 
BASMC was not diminished at all by heparitinase and 
only slightly by chlorate treatment. Accordingly, the 
role of HB-EGF interactions with HSPG in modulat- 
ing bioactivity was examined. Heparitinase or chlorate 
treatment of BASMC diminished the ability of HB- 
EGF to stimulate BASMC migration by 60-80%.  A 
similar inhibition of migration occurred when BASMC 
were treated with a synthetic peptide (P21) corre- 
sponding to the sequence of the putative heparin- 
binding domain of HB-EGE As a control for BASMC 
viability, and for specificity, it was found that hepari- 
tinase and P21  did not inhibit at all and chlorate in- 
hibited only slightly the stimulation of BASMC migra- 
tion by PDGF AB.  Since heparitinase, chlorate, and 
P21  treatment also diminished by 70-80%  the cross- 
linking of mI-HB-EGF to the EGF receptor, it was 
concluded that the interaction of HB-EGF, via its 
heparin-binding domain, with cell surface HSPG was 
essential for its optimal binding to the EGF receptor 
on BASMC and hence for its optimal ability to stimu- 
late migration. 
H  EPAltlN-binding EGF-like growth factor (HB-EGF)' 
is a recently described member of the EGF family 
that was first  identified  as a  secreted product of 
macrophages and macrophage-like cells (1, 2, 9, 10). Subse- 
quently, HB-EGF has been found to be expressed by vascular 
endothelial cells (28), vascular smooth muscle cells (5, 5a), 
and to be a component of wound fluid (17). HB-EGF, which 
has been found to contain up to 86 amino acids (10) is sig- 
nificantly longer than EGF and the structurally homologous 
mitogen, TGF-o~, which have sizes of  53 and 50 amino acids, 
respectively (4).  The COOH-terminal region of HB-EGF 
contains six cysteine residues with the spacing characteristic 
of members of the EGF family (4) and shares  ,~40 % se- 
quence identity with EGF and TGF-ot. Comparative struc- 
tural examination suggests that HB-EGF is analogous to an 
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1. Abbreviations used in this paper: BASMC, bovine aortic smooth muscle 
cells; I-IB-EGF, heparin-binding EOF-like growth factor; HS, heparan  sul- 
fate;  HSPG,  heparan sulfate  proteoglycan;  VEGF,  vascular endothelial 
growth factor. 
NH2-terminally extended form of EGF and TGF-c~. Since 
EGF and TGF-a do not bind to heparin (2,  13) while HB- 
EGF binds tightly to heparin affinity columns and is eluted 
with 1-1.2 M NaC1 (2,  9,  10), it appeared likely that the 
heparin-binding  domain of I-1B-EGF would be somewhere 
upstream of the COOH-terminal EGF, TGF-o~-like  domain. 
Site-directed mutagenesis of HB-EGF and studies with pep- 
tide fragments have indicated that the heparin-binding  se- 
quences of HB-EGF reside primarily in a twenty one-amino 
acid stretch upstream of and slightly overlapping the EGF- 
like domain (Thompson, S., S. Rigashiyama,  K. Wood, M. 
Klagsbrun,  and J. A6mham, manuscript in preparation). 
HB-EGF is as active as PDGF but considerably more po- 
tent than EGF or TGF-a in stimulating bovine aortic smooth 
muscle cells (BASMC) proliferation  (9) and migration (as 
shown in this report). The enhanced potency compared to 
EGF and TGF-ot occurs despite the fact that all three EGF 
family members apparently  bind to the same high affinity 
EGF receptor (4, 9). One possible explanation is differential 
binding to HSPG. Previous studies have shown that the inter- 
action of two other beparin-binding  growth factors,  bFGF 
and vascular endothelial  growth factor (VEGF), with cell 
surface heparan sulfate proteoglycan (HSPG), is an essential 
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mitogenic activity (7,  15, 24, 27).  These conclusions were 
based on experiments that used (a) cells mutant in heparan 
sulfate biosynthesis, (b) cells whose cell surface HSPG was 
depleted by heparitinase digestion of heparan sulfate, and (c) 
cells incubated with chlorate to block the sulfation of hepa- 
ran  sulfate.  These  results  suggested that heparin-binding 
growth factors in general might be dependent on a  dual 
receptor system consisting of HSPG and a high affinity  tyro- 
sine kinase receptor that mediates cell signaling. Given that 
HB-EGF has a strong affinity for immobilized heparin (9), 
we wanted to determine whether it could bind to cell surface 
HSPG and whether its bioactivity, in this case the ability to 
stimulate cell migration, was dependent on interaction with 
cell surface HSPG. Accordingly, BASMC surface HSPG was 
altered by heparitinase or chlorate treatment, and a synthetic 
peptide corresponding to the putative heparin-binding do- 
main of HB-EGF was used to compete for HB-EGF binding 
to cell surface HSPG. We report here that HB-EGF binds to 
cell surface HSPG and that the binding of HB-EGF to the 
EGF  receptor  on  BASMC  and  its  ability  to  stimulate 
BASMC migration are considerably diminished when HB- 
EGF-HSPG interactions are abrogated. 
Materials and Methods 
Growth Factors 
HB-EGF was prepared from U-937 cell conditioned medium as previously 
described (9, 10). PDGF AB (23) was obtained from Creative Binmolecules 
(Hopkinton, MA).  EGF (4) was  obtained from Collaborative Research 
(Bedford,  MA). HB-EGF (2/tg) was radiolabeled with Na12SI (200 t~Ci/2 
/~1; ICN Biomedicals,  Costa Mesa,  CA) using IODO-BEADS  (Pierce, 
Rockford, IL) as previously reported (10). The specific activity of 12SI-HB- 
EGF was 55,500 cpm/ng, as calculated based on the mitogenic activity of 
radiolabeled HB-EGF for 31"3 cells compared to HB-EGF sta~rds, t2sI- 
EGF (102,800 cpm/ng) was purchased from Collaborative Research.  1251- 
bFGF (77,000 cpm/ng) was a kind gif~ of Dr. Brad Olwin (University of 
Wisconsin). 
Cells 
BASMC were routinely grown in DMEM supplemented with 10% BCS, 
100  U/ml penicillin and  100  t~g/mi streptomycin sulfate  (DMEM/10% 
BCS/PS) as previously described (9, 29). Wild-type (K1) CHO cells and 
mutant CHO 803 cells,  which synthesize '~,5-10% of  the normal amount 
of HSPG, were routinely grown in Ham's F12 medium supplemented with 
10% BCS as previously  described (27). 
BASMC Migration 
The migration of BASMC was assayed in a Boyden chamber (3, 8).  Sub- 
confluent BASMC  were detached from lO-cm culture dishes by incuba- 
tion with trypsin-EDTA  (0.05%  trypsin, 0.5  mM EDTA,  GIBCO BRL, 
Gaithersburg, MD) at 370C. To avoid excessive exposure to trypsin, the in- 
cubations were carried out for as short a time as possible, usually 1 min 
or less. The cells were washed first in DMEM, 10% BCS, and then in bind- 
ing buffer A (DMEM, 20 mM Hepes,  pH 7.4, 0.5% BSA) twice, resus- 
pended in the same medium, and the cell number was then adjusted to 105 
cells/ml.  To set up the migration assay, samples to be tested for stimulation 
of BASMC migration were first added to the bottom wells of a 48-well Boy- 
den chamber (Neuro Probe Inc., Cabin John, MD) and an 8-/~m pore size 
polyvinylpyrrolidone-free  polycarbonate membrane (Nenro  Probe  Inc.) 
precoatad with fibronectin (100 t~g/ml in PBS,  Cappel Organou Teknika 
Corp.,  West Chester,  PA) was  placed above these wells.  50 /d of the 
BASMC suspension were then added to the upper wells of  the 48-well chain- 
bar and the chamber was assembled and incubated for 4 h at 37"C in a hu- 
midified atmosphere of air/10%  CO2. Cells adhering to the upper surface 
of the filter membrane were renxm~ by scraping with a rubber blade. Cells 
that had migrated through the filter were fixed with buffered formalin over- 
night, and then stained with Gill's hematoxylin overnight.  The filter was 
then mounted between two #ass slides with 90% glycerol, and the number 
of BASMC per well that had migrated across the filter was determined by 
counting the stained BASMC under a microscope. 
Binding Assays 
The ability of 125I-HB-EGF to bind to BASMC and CHO cells was mea- 
sured in binding assays carried out in 6-well plates. Briefly, confluent cells 
(3  ×  105 cells/well)  in each well were washed with ice-coid PBS/0.5% 
BSA, and incubated for 10 min at 4°C with 750-/~1  of ice-cold binding buffer 
A.  125I-EGF (0.125 ng/750/d/well,  12,800  cpm) or 125I-HB-EGF (0.25 
ng/750/~l/well,  13,900 cpm) were added to wells of the plates and the plates 
were incubated on a shaker at 4°C for 2 h. The wells were then washed three 
times with ice-cold binding buffer A, and twice with ice-cold  PBS/0.5% 
BSA. Total binding was measured by determining the amount of radioactiv- 
ity eluted with a wash of 2 M NaCI, 20 mM Na-acetate,  pH 4.0 (18, 19, 27). 
Heparitinase and Chlorate Treatment of Cells 
BASMC and CHO cells were treated as previously described with hepariti- 
nase (24), in order to digest cell surface heparan sulfate (HS), or with chlo- 
rate,  an inhibitor of HS  sulfation (12,  24).  For heparitinase treatment, 
BASMC and CHO cells were washed three times with binding buffer A and 
incubated for 1 h at 37°C with the binding buffer (750 td/6-well plate well, 
5 ml/10-cm dish or 10 ml/15-cm dish) containing 0.01 U/ml of heparitinase 
(Seikagaku  America, Inc., Ruekville,  MD). A  second aliquot of hepari- 
tinase was then added to each well or dish to bring the concentration to 0.02 
U/ml and the incubation was allowed to proceed for another 2 h. For chlo- 
rate treatment, BASMC and CHO cells were incubated with DMEM/10% 
dialyzed BCS/PS supplememed with 30 mM Na-chlorate for 48 h. Dialyzed 
BCS was used to diminish the concentration of cysteine (a source of sulfate) 
tO 50/tM (11, 12). Heparitinase and chlorate-treated cells were used directly 
for binding and cross-linking studies, or were trypsinized and analyzed for 
response to migration factors in a Boyden chamber. It should be noted that 
chlorate appears to exert a mild toxic effect on cells,  possibly due to the 
long exposure,  48 h, of cells to low cysteine media (12). 
Receptor Cross-linking 
Cross-linking of HB-EGF and EGF to the EGF receptor was carried out 
using methods previously described (26, 27). Briefly, confluent monolayers 
of BASMC (107 cells) in 15-cm dishes were washed twice with ice-cold 
2 M NaC1, 20 mM Na-acetate,  pH 4.0, in order to remove any bound en- 
dogenous BASMC-derived  I-IB-EGF or EGF. The cells were then washed 
three times with ice-cold  binding buffer B (20 mM Hepes,  pH 7.4, 0.5% 
BSA,  1 mM MgCI2,  1 #M KI in DMEM) and the monolayers  were in- 
cubated at 4°C for 2 h in binding buffer B containing nSI-HB-EGF (13.3 
ng/7.5  ml/15-cm dish,  738000 cpm) or  125I-EGF (9.4  ng/7.5  ml/15-cm 
dish, 966000 cpm). After the incubation, the cells were washed twice with 
ice-cold PBS, pH 7.4, containing 0.5% BSA, 1 mM MgCI2, and 1 #M KI, 
and then twice with ice-cold  PBS.  Bound t25I-growth factor was  cross- 
linked to cells by the addition of disuc~inimidyl  suberate (DSS;  Pierce, 
Rockford, IL) at a final concentration of 30 t~M in PBS for 20 min at room 
temperature.  After free-reactive  DSS was quenched with a large excess of 
10 mM Tris-HCl, pH 7.5, 150 mM glycine, the cells were washed with ice- 
cold PBS, and then scraped and lysed in 400 t~l of lysis buffer (1% Nonidet 
P-40  [Pierce],  1% deoxycholate  [Aldrich Chem.  Co.,  Milwaukee,  WI], 
0.1% SDS,  1% aprotinin [Bochringer Mannheim Corp., Indianapolis, IN], 
1 mM PMSF [Pierce], 2 mM EDTA,  10 mM sodium fluoride,  10 mM so- 
dium pyrophosphate,  0.4 mM sodium orthovanaclAte, I0 mM iodoaceto- 
amide [Aldrich] in PBS). Samples (30/d) were subjected to SDS-PAGE and 
125I-labeled bands we~  visualized and quantitated by analysis using a 
Pbosphorlmnger device (Molecular Dynamics,  Sunnyvale,  CA). 
Characterization of a Synthetic Peptide Corresponding 
to the Heparin-binding Domain of  HB-EGF 
A synthetic peptide corresponding to the putative 21-amino acid heparin- 
binding sequence KRKKKGKGLGKKRDPCLRKYK  of human HBoEGF 
(amino acids 93-113 of the 208 residue precursor [9]) was synthesized using 
an Applied Biosystems Peptide Synthesizer (courtesy of Margaret Ehrhardt 
[Brigham and Women's Hospital, Boston, MA]). To determine the effect of 
P21 on the binding of HB-EGF to heparin-Sepbarose,  40/tl of 50% heparin- 
Sepharose  (Pharmacia) in 10 mM Tris-HCl, pH 7.4, 0.2 M NaCI, were 
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HB-EGF 
HB-EGF Binds to Cell Surface HSPG 
HB-EGF binds to immobilized heparin (2, 9, 10). To demon- 
strate that HB-EGF can also bind to cell surface HSPG, the 
ability of ~25I-HB-EGF to bind to CHO cells was measured 
in  several  ways  (Fig.  1).  CHO  cells  possess  cell  surface 
HSPG but little  if any EGF receptor.  The binding of '~I- 
HB-EGF to mutant CHO cells which are deficient in HSPG 
biosynthesis was diminished by •70%  in comparison to the 
binding of '25I-I-IB-EGF to wild-type CHO cells (Fig.  1 A). 
In addition, treatment of CHO cells with heparitinase which 
degrades  cell  surface  HSPG,  or  chlorate  which  inhibits 
HSPO sulfation, diminished ~I-HB-EGF binding by '~80% 
(Fig. 1 B). Taken together, it appears that the binding of HB- 
EGF to CHO cells is markedly reduced in the absence of 
HSPG and that therefore I-IB-EGF  binds to CHO cell surface 
HSPG.  On the other hand,  '25I-EGF did not bind at all to 
CHO cells consistent with its inability  to bind to immobi- 
lized heparin  (2) (Fig.  1  C). 
Since we were interested  in analyzing the role of HSPG 
in  modulating  HB-EGF biological  activity  towards  SMC, 
125 I-HB-EGF  ~aSI-HB-EGF [ ~=SI-EGF 
A  B  C 
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HSPG  WT  WT +  WT +  WT  WT 
Mutant  Untreated Hep'ase  Chlorate 
F/gure L Binding of HB-EGF to CHO cells.  The relative binding 
of total  nsI-HB-EGF and 'UI-EGF to CHO cells was measured 
under different conditions.  (A) Binding of I~I-I-IB-EGF (0.25 rig, 
13,900 cpm) to 3  x  105 confluent wild-type (WT) CHO cells and 
mutant CHO 803 cells deficient  in HSPG synthesis  (HSPG  Mu- 
tam).  (B) Binding of 125I-IB-EGF  (0.25 rig, 13,900 cpm) to wild- 
type CHO cells  (Untreated) and CHO cells incubated with he- 
paritinase (Hep'ase) and chlorate as described in Materials and 
Methods. (C) Binding of nSI-HB-EGF (0.25 ng, 13,900 cpm) and 
t25I-EGF (0.125 ng,  12,800 clam) to wild-type CHO cells.  Under 
these conditions,  wild-type CHO cells bind *5,000 cpm of t25I- 
HB-EGF and 50 cpm of '25I-EGE 
§ loo 
~.  4o 
~  20 
--2.' 
0 
Heparitinase  Chlorate 
EGF 
mixed with 40 #1 of the same buffer containing increasing amounts of/21 
and constant amounts of nsI-I-IB-EGF  (0.25 ng, 13,900 cpm), ~25I-EGF 
(0.125 ng, 12,800 clam  ), and 125I-bFGF  (0.27 ng, 20,800 cpm). The mix- 
tures were incubated for 5 min at room temperature, after which the 
heparin-Sepbarose was washed four times with 400/~l of 10 mM Tris-HC1, 
pH 7.4 and counted  in a gamma  counter (Beckman  Gamma  5500). To moni- 
tor the effects of P21 on the stimulation of migration by HB-EGF, BASMC 
(60-70% confluent)  were trypsinized, washed with DMEM, 10% BCS, in- 
cubated with binding buffer A, incubated with 25/=g/ml/21 in binding 
buffer A for 10 min at 37°C, and washed three times with the binding  buffer 
to remove nonbound/21. The BASMC  pretreated with/21 were analyzed 
for the response to migration factors in a Boyden  chamber. To monitor the 
effects of/21 on cross-linking, BASMC  were incubated with 25/~g/ml/21 
and either '25I-HB-EGF  or '25I-EGF  on ice, and cross-linking was mea- 
sured as described above. 
EGF  HB-EGF 
[]  Untreated  •  Treated 
Figure 2.  Effects of heparitinase  and chlorate on binding of 125I- 
HB-EGF to BASMC.  BASMC treated (black bars) with hepari- 
tinase or chlorate were incubated  with 125I-I-IB-EGF  or '25I-EGF 
as in Fig.  1 and total binding relative  to untreated cells  (gray- 
hatched bars) was measured. (LEFT) Binding of '25I-I-IB-EGF or 
'~I-EGF to heparitinase-treated  or untreated  cells. (R/GHT)  Bind- 
ing of '25I-I-IB-EGF or ~25I-EGF to chlorate-treated  or untreated 
cells.  Total  binding  of '25I-HB-EGF  and  '25I-EGF to untreated 
cells  was  •3,600  cpm and  1,500  cpm,  respectively.  The back- 
ground count in the absence of '25I-growth factor was ~40 cpm. 
'25I-HB-EGF binding  to  BASMC  was  measured.  Unlike 
CHO cells, SMC mutant in HSPG biosynthesis are not avail- 
able and these cells possess EGF receptor (9). Nevertheless, 
both heparitinase  and chlorate diminished  total binding of 
'25I-HB-EGF to BASMC by 80%  (Fig. 2), an amount simi- 
lar to that produced by these treatments of CHO cells. Thus, 
it is apparent that HB-EGF binds to BASMC HSPG in addi- 
tion to the EGF receptor. On the other hand, heparitinase did 
not diminish at all '2q-EGF binding to BASMC while chlo- 
rate  reduced  125I-EGF  binding  by  25%.  Taken  together, 
these results suggest that EGF, unlike HB-EGF, binds very 
poorly, if at all,  to BASMC HSPG. 
The Ability of HB-EGF to Stimulate BASMC 
Migration Is Dependent on Interactions with Cell 
Surface HSPG 
It had been previously shown that HB-EGF is a potent mito- 
genie factor for BASMC, with half-maximal activity at 100 
pg/ml (9). The mitogenic activity of HB-EGF was compara- 
ble to PDGF but its specific activity was 30-40 times greater 
than EGE Using a Boyden chamber migration assay, it is ap- 
parent that this is true for migration as well.  HB-EGF is a 
potent stimulator of BASMC migration, with a half-maximal 
stimulation at  150 pg/mi (Fig.  3), and  100 pg/mi HB-EGF 
is as active as 330 pg/mi PDGF AB and 3.3 ng/mi EGE 
Since I-IB-EGF, but not EGE binds to HSPG, the relation- 
ship  betw~n  growth  factor-mediated  biological  activities 
and interactions with cell surface HSPG was subsequently 
analyzed. Migration rather than mitogenic activity was mea- 
sured in this analysis because the shorter duration of migra- 
tion  assays  (4  h)  compared  to  mitogenic  assays  (72  h) 
minimized the amount of time needed to measure the effects 
of growth factors on BASMC treated in various ways. Ac- 
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Figure 3. Stimulation of BASMC migration. Migration was mea- 
sured in a Boyden  chamber assay. BASMC were exposed to increas- 
ing concentrations of HB-EGF (closed circles), PDGF AB (open 
circles), and EGF (triangles) in the lower wells of a Boyden cham- 
ber and the number of cells per well migrating across the polycar- 
bonate membrane in the chamber was measured. Each point is the 
average of  quadruplicate measurements. The background migration 
in the absence of growth factor was 20 +  5 cells/well. 
cordingly, stimulation of migration by HB-EGF was mea- 
sured on BASMC that had been incubated for either 3 h with 
heparitinase or for 48 h with chlorate (Fig. 4 A). Both treat- 
ments markedly inhibited the ability of HB-EGF to stimulate 
migration at all concentrations tested. At the concentration 
of maximal I-IB-EGF stimulation,  1 ng/rnl, heparitinase or 
chlorate-treated BASMC migration was diminished by 80%. 
1 ng/ml HB-EGF was needed to stimulate the migration of 
treated BASMC to the same extent as did  150 pg/ml HB- 
EGF for untreated BASMC. Indeed, the ability of HB-EGF 
to stimulate BASMC depleted of HSPG was more compara- 
ble to that typically seen for EGF on BASMC with a normal 
complement of cell surface HSPG.  Taken together, these 
results  suggested  that  the  ability  of HB-EGF  to  induce 
migration of BASMC is reduced markedly if the cells are di- 
minished in available or intact cell surface HSPG. For com- 
parison and as a control for SMC viability, the activity of 
PDGF AB, a potent stimulator of SMC migration (23), was 
measured on BASMC treated with heparitinase or chlorate 
(Fig. 4 B). The ability of PDGF AB to stimulate BASMC 
migration was not diminished at all by heparitinase suggest- 
ing that this treatment was not toxic for SMC nor was the 
availability of  cell surface HSPG an absolute requirement for 
migration. Chlorate, on the other hand, did diminish PDGF 
AB-stimulated migration but by only •20%. 
Inhibition of HB-EGF-stimulated BASMC 
Migration by a Heparin-binding Domain Synthetic 
Peptide Analogue 
Another approach to determining the importance of HB- 
EGF interactions with SMC HSPG would be to interfere 
with the ability of HB-EGF to bind to cells via its heparin- 
binding  domain.  A  putative  heparin-binding  domain  in 
human HB-EGF has been identified by site-directed muta- 
genesis  and peptide  fragment studies  (Thompson,  S.,  S. 
2001- A)  HB-EGF 
10(  Hep'ase 
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Figure 4. Migration of BASMC preincubated with hcparitinas¢ or 
chlorate.  BASMC were  either  left  untreated  (closed circles), 
pretreatexi with  heparitiuase  (Hephse)  for  3  h  (squares), or 
pretreated with chlorate for 48 h (open circles). Migration of these 
cells in response to increasing concentrations of (A) HB-EGF and 
(B) PDGF AB was measured as in Fig. 3. Each point is the average 
of quadruplicate values. The background migration in the absence 
of I-1B-EGF  or PDGF was 17 +  5 and 15 :t: 4 cells/well, respec- 
tively. 
Higashiyama, K.  Wood, M.  Klagsbrun,  and J.  Abraham, 
manuscript in preparation).  The results  of this  study are 
summarized in Fig.  5 A which shows a putative heparin- 
binding domain of 21 amino acids (amino acids 31-51 of the 
mature 86-amino acid form of HB-EGF [10]).  A 21-amino 
acid synthetic pcptide corresponding to this domain, desig- 
nated as P21, was prepared and tested for the ability to inter- 
fere with the binding of HB-EGF to heparin-Sepharose (Fig. 
5 B). The l~ptide inhibited half-maximally binding of 125I- 
HB-EGF to heparin-Sepharos¢ at a  concentration of ,x,2 
mg/ml.  On  the  other  hand,  I:SI-EGF  did  not  bind  to 
beparin-Sepharose at all consistent with previous observa- 
tions (13) and therefore was unaffected by P21. Interestingly, 
the binding of I~I-bFGF, a growth factor with a very strong 
affinity for heparin and HSPG (13), to heparin-Sepharose 
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Figure 5. Inhibition of HB-EGF binding to heparin-Sepharose  by 
a synthetic peptide corresponding to a putative heparin-binding do- 
main of HB-EGE (A) The sequence of mature HB-EGF (9, 10) with 
the location of its 21-amino acid putative heparin-binding domain 
(residues  31-51 of HB-EGF) outlined in gray. (B) The synthetic 
peptide (P21) corresponding to residues 31-51 was tested in a dose- 
dependent  manner for its effect on the  binding  of nSI-HB-EGF 
(closed circles), '25I-EGF (open circles) or t25I-bFGF (triangles) 
to heparin-Sepharose as described in Materials and Methods. Bind- 
ing of '251- growth factor in the presence of P21 is plotted relative 
to control values in the absence of P21 except n5I-EGF which is 
plotted relative to 125I-HB-EGE Under the conditions of these ex- 
periments,  the  control  binding  of  125I-bFGF (0.27 ng,  20,800 
cpm), 125I-HB-EGF  (0.25 ng,  13,900 cpm), t25I-EGF (0.125 ng, 
12,800  cpm) to  heparin-Sepharose  in  the  absence  of P21  was 
15,670, 5,600, and 50 cpm, respectively. 
A) HB-E 
B)  PDGF  ~. 
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Figure 6. Effect of the synthetic peptide, P21, on BASMC migra- 
tion.  Stimulation of BASMC migration in response to increasing 
concentrations of (,4) HB-EGF or (B) PDGF AB, was measured in 
the absence of (closed circles) and in the presence of 25 ttg/ml P21 
(open circles). Each point is the average of quadruplicate  values. 
The background migration in the absence of HB-EGF and PDGF 
AB was 23  -1- 6 and  12  +  4 cells/well,  respectively. 
was not inhibited by P21 suggesting that bFGF has a different 
heparin-binding domain than HB-EGE 
At the concentration of maximal HB-EGF stimulation,  1 
ng/ml, the P21  peptide at 25 #g/ml inhibited the ability of 
HB-EGF to stimulate BASMC migration by •60%  (Fig. 6 
A). One ng/ml HB-EGF was needed to stimulate the migra- 
tion of P21-treated BASMC to the same extent as did 200 
pg/ml HB-EGF for untreated BASMC.  On the other hand, 
P21 did not inhibit the ability of PDGF to stimulate BASMC 
migration demonstrating that the synthetic peptide was not 
toxic and did not interfere with BASMC migration in a non- 
specific manner (Fig. 6 B). Nor did P21 inhibit any further 
the  relatively  poor  ability  of EGF  to  stimulate  BASMC 
migration (not shown). Taken together, these results demon- 
strated  further  that  the  ability  of  HB-EGF  to  stimulate 
BASMC migration is modulated by its heparin-binding prop- 
erties. 
Effects of Heparitinase,  Chlorate, and 1'21 
on Receptor Crass-linking 
'25I-EGF and  '25I-HB-EGF could  both  be cross-linked  to 
BASMC to form labeled complexes of '~,170 kD (Fig.  7). 
These  complexes  comigrated  with  ligand-EGF  receptor 
complex standards  prepared by cross-linking  12~I-EGF or 
'2SI-HB-EGF  to  A431  cells  (not  shown),  nSI-HB-EGF 
cross-linking  was  inhibited  by excess cold  EGF and  125I- 
EGF cross-linking was inhibited by excess cold I-IB-EGF 
supporting the previous conclusion that EGF and I-IB-EGF 
bind to the same EGF receptor (9) (not shown).  The syn- 
thetic peptide,  P21,  inhibited the cross-linking of 125I-I-IB- 
EGF (lane 2) to BASMC by ru75 %, comparable in degree 
to the inhibition of cross-linking caused by chlorate (lane 3) 
and heparitinase (lane 4) treatment of BASMC. On the other 
hand, P21 did not inhibit '25I-EGF cross-linking to BASMC 
(lane  6)  nor did heparitinase  (lane  8).  Chlorate inhibited 
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EGF and EGF to the EGF recep- 
tor  on  treated  and  untreated 
BASMC.  BASMC were  either 
untreated  or  exposed to  hepar- 
itinase, chlorate, or 25/zg/ml of 
the synthetic peptide,  P21. The 
ceils were incubated with either 
t25I-HB-EGF (lanes 1-4) or 125I- 
EGF  (lanes 5-8).  After  cross- 
linking,  samples were subjected 
to SDS-PAGE, and bands  were 
visualized (Top) and quantitated 
by phosphor-Imaging (Bottom) as 
described  in  Materials  and 
Methods.  The  growth  factor 
complexes  formed  comigrated 
with an EGF-EGF receptor com- 
plex standard prepared by cross- 
linking  12q-EGF to  A431 cells 
(data not shown). 
12SI-EGF cross-linking slightly, by ,x,20%  (lane 7), consis- 
tent with the EGF-BASMC binding studies shown in Fig. 2. 
In conclusion, using several different approaches, it is ap- 
parent that the binding of HB-EGF to BASMC surface HSPG 
is required for its optimal binding to the EGF receptor and 
that these HB-EGF-HSPG interactions facilitate the ability 
of I-1B-EGF to stimulate migration of BASMC. 
Discussion 
HB-EGF, but not the structurally homologous protein EGE 
is a heparin-binding growth factor (2, 9). The fact that both 
HB-EGF and EGF bind to the EGF receptor (9) combined 
with the possibility that HB-EGF, but not EGE binds to cell 
surface HSPG, affords an excellent opportunity to ask the 
question of whether I-IB-EGF binding to HSPG modulates 
its bioactivity. The ability of HB-EGF to bind to cell surface 
HSPG can be demonstrated by using mutant CHO cells that 
synthesize only 5--10% of their normal cell surface HSPG. 
These HSPG deficient cells bind 125I-HB-EGF only 30% as 
well as do the wild-type CHO cells. In addition, binding to 
wild-type CHO cells is diminished by 80% after treatment 
of cells with heparitinase which destroys cell surface HSPG 
and with chlorate which blocks sulfation of HSPG. Since we 
have found that the  CHO  cells express little if any EGF 
receptor, these experiments suggest strongly that I-IB-EGF 
is capable of binding to cell surface HSPG.  On the other 
hand,  mz~I-EGF does not bind to  CHO cells  suggesting  a 
lack of interaction with cell surface HSPG. 
To analyze the effects of HSPG on I-IB-EGF bioactivity, we 
chose to study BASMC because of the previous demonstra- 
tion that HB-EGF is a far more potent mitogenic factor for 
these cells than EGF (9) and the subsequent demonstration 
(Fig. 3) that this enhanced potency is true for I-IB-EGF stim- 
ulation of BASMC migration as well. It is apparent that HB- 
EGF binds to BASMC HSPG since treatment of these cells 
with heparitinase or chlorate diminishes t2~I-HB-EGF bind- 
ing by "~80%.  Using the migration assay,  it appears that 
methods that interfere with HB-EGF-SMC HSPG interac- 
tions also inhibit HB-EGF activity. For example, the ability 
of HB-EGF to stimulate BASMC migration is considerably 
diminished, by "~70-80%, when these cells are treated with 
heparitinase or with chlorate. Furthermore, a synthetic pep- 
tide, P21, corresponding to the putative heparin-binding do- 
main of HB-EGF (a 21-amino acid stretch just upstream and 
slightly overlapping the EGF-like domain [Thompson, S., S. 
Higashiyama,  K.  Wood,  M.  Klagsbrun,  and J.  Abraham, 
manuscript in preparation] that blocked HB-EGF, but not 
bFGF,  binding  to heparin-Sepharose),  inhibited HB-EGF 
stimulation of  BASMC migration by ,,060%. As a control for 
the possibility that heparitinase, chlorate, or P21 treatment 
might be toxic to BASMC and inhibit migration directly, it 
was demonstrated that heparitinase and P21 did not diminish 
at all, while chlorate diminished slightly, the potent ability 
of PDGF AB to stimulate BASMC migration. It should be 
pointed out, however, that chlorate treatment resulted con- 
sistently in a 20-25 % inhibition of binding and migration, 
possibly due to cell toxicity caused by the long exposure, 
48 h, of BASMC to low cysteine media. The lack of PDGF 
dependence on HSPG-binding is consistent with the rela- 
tively low affinity of PDGF for heparin-Sepharose. PDGF 
which has a pI of 9.8, is eluted from heparin-Sepharose with 
0.5 M  NaC1,  typical of basic proteins that bind to heparin 
due to cation-anion charge interactions rather than to any in- 
trinsic heparin affinity (13). Treatments aimed at abrogating 
growth factor-HSPG interactions also had no effect on the 
relatively poor ability of EGF to stimulate BASMC migra- 
tion consistent with the inability of EGF to bind to immobi- 
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pears that if HB-EGF is prevented access to intact BASMC 
HSPG by either HSPG degradation,  HSPG desulfation, or 
by a peptide that competes for HB-EGF binding to HSPG, 
it is no longer optimally bioactive and acts more like EGF, 
a relatively poor stimulator of BASMC migration. 
How  do  HB-EGF-HSPG  interactions  modulate  bioac- 
tivity?  In cross-linking experiments in which formation of 
growth  factor-EGF  receptor  complexes can be  visualized 
and quantitated,  it was found that heparitinase-,  chlorate-, 
or P21-treated BASMC display considerably diminished, by 
,o70-80%,  HB-EGF covalent cross-linking to the tyrosine 
kinase EGF receptor. On the other hand, heparitinase and 
P21 had no inhibitory effect and chlorate a slight inhibitory 
effect on EGF cross-linking to the BASMC  EGF receptor 
consistent with the relative inability of EGF to bind to im- 
mobilized heparin or to cell surface HSPG and consistent 
with the lack in EGF of the heparin-domain present in HB- 
EGF.  These results  suggest that the ability of HB-EGF, but 
not EGF, to bind to the EGF receptor is dependent on its 
ability to bind to cell surface HSPG.  Dependence of HB- 
EGF binding and bioactivity on a dual receptor system con- 
sisting of cell surface HSPG, perhaps acting as low affinity 
receptors, and the EGF tyrosine kinase receptor, is consis- 
tent  with results  found previously  for two other heparin- 
binding growth factors, bFGF and VEGF (7,  15, 24, 27). 
The actual  mechanisms by which binding to cell surface 
HSPG modulates the bioactivity of heparin-binding growth 
factors such as HB-EGF, bFGF, or VEGF are not well un- 
derstood. Possible mechanisms are that: (a) HSPG concen- 
trates  heparin-binding  growth  factors  on  the  cell  surface 
making them more available to the cell (13), (b) HSPG stabi- 
lizes or alters  the conformation of heparin-binding growth 
factors  and/or  their  receptors,  thereby  increasing  ligand- 
receptor affinity  (27),  (c) HSPG stabilizes heparin-binding 
growth factor dimerization in turn facilitating receptor di- 
merization  as  suggested  for  bFGF  (22),  and  (d)  HSPG 
lowers the  off-rate  component  of binding  to high  affinity 
receptor by heparin-binding growth factors. For example, it 
has been demonstrated that the loss of HSPG increases the 
off-rate of binding ofbFGF to its high affinity tyrosine kinase 
receptor (20). 
The identification of growth factors that are potent stim- 
ulators  of SMC  migration and proliferation could be sig- 
nificant  in  delineating  the  causes  of  pathological  SMC 
hyperplasia that occurs in restenosis after angioplasty,  in ath- 
erosclerosis, and in hypertension (14, 25). It has been pro- 
posed that growth factors such as PDGF and bFGF may be 
involved in the SMC migration and proliferation that occurs, 
for example, after intra-arterial  injury induced by a balloon 
catheter  (6,  16,  21).  HB-EGF  might play  a  role in these 
migration and proliferative processes as well since prelimi- 
nary analysis indicates that the levels of HB-EGF mRNA rise 
markedly as early as 2 h postballoon injury in the rat carotid 
artery (Chat), S., M. Reidy, S. Dluz, D. Damm, J. Abraham, 
and M. Klagsbrun, manuscript in preparation).  Analysis of 
how  HB-EGF  structure  affects  its  biological  activity  for 
SMC,  for example via heparin-binding,  might be useful in 
learning how SMC  growth is regulated and in developing 
strategies for antagonizing SMC migration and proliferation 
under pathological conditions. 
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